Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. AtriCure preps $150m offering
AtriCure registered for a securities offering worth $150 million that could bring in another $115 million for some of its stockholders in a secondary offering.
West Chester, Ohio-based AtriCure said its portion of the flotation could include common stock, preferred stock, debt securities, warrants or depositary shares and units. The company won’t get any proceeds from the secondary offering of nearly 5.6 million shares, according to a regulatory filing. Read more
4. Mainstay Medical pulls in $34m for Reactiv8 neurostim device for chronic pain
Mainstay Medical said last week that it raised a $34 million (€30 million) equity round for its Reactiv8 neurostimulation device, including a $17 million (€15 million) contribution from family investment fund KCK.
Proceeds from the 2.3-million-share flotation, priced at $14.70 apiece (€13.00), are slated for European commercialization of the Reactiv8 device (the system won CE Mark approval in the European Union last month for treating chronic lower back pain). Mainstay said it also plans to spend the cash on clinical trials ahead of a bid for pre-market approval in the U.S. Read more
3. Cerus, Terumo land $48m in BARDA grants for anti-Zika push
Cerus and Terumo Corp. won grants from a U.S. Health & Human Services Dept. agency worth a collective $48 million to study their respective devices for eliminating blood pathogens like the Zika virus.
Zika, which the World Health Organization declared a global emergency in February, has been linked to microcephaly, a birth defect characterized by an unusually small head and potential developmental problems. Read more
2. CVRx raises $47m, with another $25m in the pipeline
CVRx raised $46.5 million and has another $25.1 million waiting in the wings once it achieves “a certain milestone,” the company said in a regulatory filing last week.
Seventeen unnamed investors participated in the round, according to the filing, taking Minneapolis-based CVRx’s total raise since its 2001 founding to $237.1 million. Read more
1. FDA allows emergency use of Hologic’s Aptima test for the Zika virus
Hologic said it won an emergency use exemption from the FDA for its Aptima diagnostic to detect Zika virus.
The approval covers the detection of the Zika virus in human serum and plasma specimens and makes the test available immediately in the U.S., Puerto Rico and U.S. territories, Marlborough, Mass.-based Hologic said. Read more
